ArticleTrials2026
Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSickle cell disease (SCD) is a genetic disorder characterized by chronic hemolysis and vaso-occlusive crises. Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has shown promise in treating SCD by stimulating erythropoietin production in a similar manner that happens in response to hypoxia, promoting erythropoiesis and improving iron metabolism, leading to increased hemoglobin and RBC indices.
methodsThis was a phase IIa, double-blind, randomized, placebo-controlled, parallel-group, proof-of-concept, multicenter clinical trial designed to evaluate the efficacy and safety of desidustat in Indian adults with sickle cell disease (SCD). A total of 24 participants were enrolled based on predefined eligibility criteria, with 8 subjects per dose cohort (50 mg, 100 mg, and 150 mg), randomized in a 3:1 ratio (desidustat:placebo). The study included a screening period of up to 4 weeks, an 8-week treatment phase, and a follow-up visit at week 10, totaling 98 days. Efficacy (hemoglobin response rate) was assessed at week 8 relative to baseline compared to placebo. Dose adjustment of desidustat at week 4 was guided by hemoglobin levels measured using a calibrated HemoCue instrument. DISCUSSION: Management of sickle cell disease (SCD) has limited treatment modalities available like hydroxyurea and blood transfusions. They offer benefits but their limitations underscore the ongoing need for safer, more effective, and accessible treatments. This proof-of-concept trial was conducted to investigate the efficacy and safety of desidustat oral tablet, 3 times per week for 8 weeks in SCD patients. Results from this trial could aid in establishing a cost-efficient therapeutic option for managing rare diseases like SCD.
trial registrationThe study was approved by Central Drugs Standard Control Organization (CDSCO: CT NOC number CT/SND/27/2023, protocol number DESI.23.001, version no. 01 registered on 12 June 2023) and was conducted for a new drug as per the GCP guidelines. The first subject was screened on 7 January 2025 and the last visit of the last subject was conducted on 31 July 2025, followed by clinical study report finalization on 29 September 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.